

World J Stem Cells. 2015 Jan 26;7(1):116-25.
doi: 10.4252/wjsc.v7.il.116.

- 6) Kodaira M, Hatakeyama H, Yuasa S, Seki T, Egashira T, Tohyama S, Kuroda Y, Tanaka A, Okata S, Hashimoto H, Kusumoto D, Kunitomi A, Takei M, Kashimura S, Suzuki T, Yozu G, Shimojima M, Motoda C, Hayashiji N, Saito Y, Goto Y, Fukuda K. Impaired respiratory function in MELAS-induced pluripotent stem cells with high heteroplasmy levels. FEBS Open Bio. 2015 Mar 20;5:219-25. doi: 10.1016/j.febs.2015.03.008. eCollection 2015.
- 7) Hayashiji N, Yuasa S, Miyagoe-Suzuki Y, Hara M, Ito N, Hashimoto H, Kusumoto D, Seki T, Tohyama S, Kodaira M, Kunitomi A, Kashimura S, Takei M, Saito Y, Okata S, Egashira T, Endo J, Sasaoka T, Takeda S, Fukuda K. G-CSF supports long-term muscle regeneration in mouse models of muscular dystrophy. Nat Commun. 2015 Apr 13;6:6745. doi: 10.1038/ncomms7745.

2. 学会発表

- 1) Seki T, Kusumoto D, Kishino Y, Tohyama S, Okada M, Nakajima K, Ohno R, Henmi N, Kunitomi A, Saito Y, Oda M, Yuasa S, Fujita J, Fukuda K. 分化誘導に適したiPS細胞株選抜を目的としたiPS細胞株間の遺伝子発現の差異の解析. 第13回日本再生医療学会総会、京都、3月、2014年
- 2) Kishino Y, Seki T, Miyamoto K, Tohyama S, Yuasa S, Fujita J, Sano M, Fukuda K. The Novel Method of Identifying Transplanted Cells Using T-cell Receptor Gene Locus. 第13回日本再生医療学会総会、京都、3月、2014年
- 3) Seki T, Yuasa S, Egashira T, Tohyama S, Yae K, Kusumoto D, Kunitomi A, Saito Y, Hashimoto H, Oda M, Kodaira M, Kuroda Y, Tanaka A, Okata S, Ohno Y, Fujita J, Kodo K, Yamagishi H, Fukuda K. Generation of Induced Pluripotent Stem Cells from Patient with Familial Atrial/Ventricular Septum Defect. 第78回日本循環器学会学術集会、東京、3月、2014年
- 4) 関倫久, 福田恵一 T細胞由来iPS細胞の再生医療への応用, シンポジウム, 再生医療を支える基盤技術の創出 第14回日本再生医療学会総会、横浜、3月、2015年

G. 知的財産権の出願・登録状況

1. 特許取得
なし
2. 実用新案登録
なし
3. その他
なし

再生医療の安全性確保のための抗腫瘍免疫誘導法の開発

研究分担者 中面 哲也 国立がん研究センター 早期・探索臨床研究センター 免疫療法開発分野長
関 倫久 慶應義塾大学 循環器内科 助教
研究協力者 岡田麻里奈 慶應義塾大学 循環器内科 助教
多田 好孝 国立がん研究センター 早期・探索臨床研究センター 免疫療法開発分野

研究要旨

自己 iPS 細胞を作成し再生医療を実施する手法は、組織不適合性問題を解決するという観点からは理想的である。しかしながら、移植細胞から腫瘍が発生した場合に、組織不適合による安全機構が働かないため、この点から考えるとむしろ危険性が高いとも言える。問題となる未分化細胞の混入とがん化の問題を解決するために、未分化細胞特異的抗原と CTL エピトープの同定を試みている。ペプチド 89 種を合成し、これらのペプチドを用いて、ヒト末梢血単核球を刺激、あるいは、ヒト HLA 遺伝子導入マウスに免疫して、誘導された CTL のペプチド特異性を解析したところ、現時点で 3 種類のペプチドにおいて特異的な CTL の誘導を確認している。機能解析を行うため、誘導された CTL からペプチド特異的 CTL クローンを樹立した。今後は、樹立した CTL クローンを用いて、未分化細胞への反応性の評価を行う。

iPS 細胞ストック由来出なく、本人由来の iPS 細胞を用いた再生医療において組織不適合性はほぼ皆無である。しかしながら、移植細胞から腫瘍が発生した場合に、組織不適合による安全機構が働かないため、腫瘍化という観点からは、iPS 細胞ストックを利用した同種異系 (アロ) 移植よりも、こちらの方が危険性が高い。自己 iPS 細胞の臨床応用においては、残存幹細胞混入による腫瘍発生を回避する技術を開発することが必須となる。本研究では、これまでの抗腫瘍免疫研究の経験を生かし、ペプチドワクチンを用いて未分化細胞のみを除去する細胞傷害性 T 細胞を誘導し、腫瘍細胞を除去する手法を検討する。

B. 研究方法

・未分化細胞抗原を標的とする iPS 細胞再生医療における腫瘍拒絶法の検討

iPS 細胞による再生医療において問題となる、未分化細胞の混入とがん化の問題を解決するために、未分化細胞特異的抗原と CTL エピトープの同定を行なう。標的抗原の候補となるタンパク質のアミノ酸配列から、ペプチド HLA 結合予測システム (BIMAS) を用いて HLA-A02、HLA-A24 に結合が予測される

9-10 個のアミノ酸からなるヒトとマウスで共通の配列が存在する未分化細胞特異的 CTL エピトープ候補ペプチドをピックアップして合成する。これらの候補ペプチドを用いて、ヒト末梢血単核球を刺激し、あるいは、ヒト HLA 遺伝子導入マウスに免疫して、誘導された CTL のペプチド特異性を解析することにより、特異的 CTL の誘導が可能な未分化細胞特異的抗原由来ペプチドを同定する。さらに、同定されたペプチドにより誘導される CTL が未分化 iPS 細胞に対して傷害能を示すかを確認する。

(倫理面への配慮)

動物を用いる実験においては「動物愛護管理法」、「実験動物の飼養及び保管並びに苦痛軽減に関する基準」、「動物実験の適正な実施に向けたガイドライン」、「厚生労働省の所轄する実施機関における動物実験等の実施に関する基本指針」を踏まえ、各施設における動物取扱の取り決めを遵守して、事前に各施設における動物実験委員会承認を得た後に行う。遺伝子組換え実験については、各施設の遺伝子組換え実験委員会の承認後に実施する。また、遺伝子改変動物の取り扱いについては「カルタヘナ法」を順守し、各施設における動物実験委員会および遺伝

子組換え実験委員会の審査を受けて実施する。国立がん研究センターおよび慶應大学医学部では、教育研究に関わる生命倫理ならびに安全管理に関する問題を審議して、これらが適切に遂行されるように、倫理審査委員会が設置され規則が整備されている。本研究において、倫理審査委員会の承認が必要な研究においては、各施設の倫理審査委員会に研究計画書を提出して承認後に行う。

C. 研究結果

NIH の Stem Cell Database からマイクロアレイのデータを入手し、GeneSpring を用いて未分化抗原の候補になる分子をリストアップした。具体的には、OCT3/4、Nanog などの 6 個の遺伝子であり、これらは、iPS 細胞に高発現し、かつ、正常な体細胞にはほとんど発現が認められないものである。まず BIMAS (Bio Informatics and Molecular Analysis) を用いて、CTL (細胞傷害性 T 細胞) による認識の標的となる未分化抗原由来エピトープペプチドの探索を行った。その結果、日本人集団において高頻度に認められる HLA クラス I である HLA-A*24:02 あるいは 02:01 に対する結合アフィニティーが高いと予測されるペプチド 89 種に関して、合成ペプチドを作成した。次に、これらのペプチドを用いて、ヒト末梢血単核球を刺激、あるいは、ヒト HLA 遺伝子導入マウスに免疫し、3 つのペプチドに対して特異的な CTL の誘導を確認した。さらに、機能解析を行うため、誘導された CTL から CD107a アッセイを用いて、CLDN6 由来ペプチド特異的 CTL クローンを樹立した。

D. 考察

自己 iPS 細胞を作成し再生医療を実施する手法は、組織不適合性問題を解決するという観点からは理想的である。しかしながら、移植細胞から腫瘍が発生した場合に、組織不適合による安全機構が働かないため、この点から考えるとむしろ危険性が高いとも言える。問題となる未分化細胞の混入とがん化の問題を解決するために、未分化細胞特異的抗原に由来する CTL エピトープの同定を試み、ペプチド 3 つを同定した。誘導されたペプチド特異的 CTL は未分化 iPS 細胞特異的な細胞傷害を示す可能性がある。誘導された CTL の機能解析を行うため、これらの CTL からペプチド特異的 CTL クローンを樹立した。今後、樹立した CTL クローンの未分化 iPS 細胞への

反応性の評価を行う。

E. 結論

未分化細胞特異的抗原由来 CTL エピトープペプチドの同定を目指して、ペプチド 89 種を合成し、これらのペプチドを用いて、ヒト末梢血単核球を刺激、あるいは、ヒト HLA 遺伝子導入マウスに免疫して、誘導された CTL のペプチド特異性を解析した結果、3 つのペプチドに対してペプチド特異的な CTL の誘導が確認された。誘導された CTL の機能解析を行うため、これらの CTL からペプチド特異的 CTL クローンを樹立した。今後は、樹立した CTL クローンの未分化 iPS 細胞への反応性の評価を行う。

F. 研究発表

1. 論文発表

- 1) Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. *Oncol. Rep.* 32(1):33-39,2014 Jul
- 2) Ofuji K, Saito K, Yoshikawa T, Nakatsura T. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. *Journal of Hepatocellular Carcinoma.* 1:35-42,2014 May
- 3) Yoshikawa T, Takahara M, Tomiyama M, Nieda M, Maekawa R, Nakatsura T. Large-scale expansion of $\gamma\delta$ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. *Int. J. Oncol.* 45:1847-1856,2014 Nov
- 4) Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. *Int. J. Oncol.* 46:28-36,2015 Jan
- 5) Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T. A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. *Int. J. Oncol.* 46:497-504,2015 Feb

2. 学会発表

- 1) がん免疫療法の開発、中面哲也、プラクティカルセッション～明日から役立つ個別化医療、第 18 回国際個別化医療学会学術集会 (札幌) 2014

年6月14日

- 2) がんワクチン開発の現状と課題、中面哲也、教育講演「がんワクチン開発の現状と課題」、第41回日本毒性学会学術年会（神戸）2014年7月2日～4日
- 3) がんに対する免疫療法の基本、中面哲也、教育セミナー「がん専門CRCのためのアドバンスセミナー」、第12回日本臨床腫瘍学会学術集会（福岡）2014年7月17日～19日
- 4) Glypican-3(GPC3) ペプチドワクチン投与後の投与局所及び腫瘍局所でのペプチド特異的CTLの解析、吉川聡明、下村真菜美、澤田雄、高橋真理、吉原宏樹、上野浩生、真部淳、細野亜古、植村靖史、中面哲也、第18回日本がん免疫学会総会（松山）2014年7月30日～8月1日
- 5) Glypican-3 由来エピトープペプチド結合リポソームのCTL誘導能の評価、岩間達章、内田哲也、下村真菜美、吉川聡明、中面哲也、第18回日本がん免疫学会総会（松山）2014年7月30日～8月1日
- 6) Analysis of glypican-3 specific CTLs in the tumor tissue and vaccination site after administration of GPC3 peptide.
(Glypican-3(GPC3) ペプチドワクチン投与後の投与局所及び腫瘍局所でのペプチド特異的CTLの解析)、吉川聡明、下村真菜美、澤田雄、植村靖史、中面哲也、第73回日本癌学会学術総会（横浜）2014年9月25日～27日
- 7) Evaluation of peptide-specific CTL-inducibility of glypican-3-derived peptide-coupled liposome vaccine.
(Glypican-3 由来ペプチドを結合したリポソームワクチンのペプチド特異的CTL誘導能評価)、岩間達章、内田哲也、下村真菜美、吉川聡明、中面哲也、第73回日本癌学会学術総会（横浜）2014年9月25日～27日
- 8) The enhancement of the CTL induction by peptide vaccine therapy in combination with anti-CD4 antibody. (抗CD4抗体の併用投与は抗腫瘍ペプチドワクチン療法のCTLプライミング効率を高める)、藤浪紀洋、吉川聡明、澤田雄、下村真菜美、岩間達章、植村靖史、中面哲也、第73回日本癌学会学術総会（横浜）2014年9月25日～27日
- 9) EGFR T790M mutation-derived antigen

provides the immunogenicity in NSCLC patients. (非小細胞肺癌におけるEGFR T790M 変異由来抗原は免疫原性を与える)、大藤和也、吉川聡明、多田好孝、吉村麻友子、下村真菜美、中本安成、中面哲也、第73回日本癌学会学術総会（横浜）2014年9月25日～27日

- 10) Glypican-3 (GPC3) ペプチドワクチン投与後の投与局所及び腫瘍局所でのペプチド特異的CTLの解析、吉川聡明、下村真菜美、澤田雄、高橋真理、植村靖史、中面哲也、第12回日本免疫治療学研究会学術集会（東京）2015年2月28日

G. 知的財産権の出願・登録状況

1. 特許取得
なし
2. 実用新案登録
なし
3. その他
なし



III. 平成25年度研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ
Takamatsu, K., Ikeda, T., Haruta, M., Matsumura, K., Ogi, Y., Nakagata, N., Uchino, M., Ando, Y., Nishimura, Y., and Senju, S.	Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2.	Stem Cell Research	13(3)	442-453
Haga, E., Endo, Y., Haruta, M., Koba, C., Matsumura, K., Takamatsu, K., Ikeda, T., Nishimura, Y., and Senju, S.	Therapy of peritoneally disseminated colon cancer by TAP-deficient ES cell-derived macrophages in allogeneic recipients.	Journal of Immunology	193(4)	2024-2033
Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T.	Identification of a novel HLA-A*02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.	Oncol. Rep.	32(1)	33-39
Ofuji K, Saito K, Yoshikawa T, Nakatsura T.	Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma.	Journal of Hepatocellular Carcinoma.	1	35-42
Kishino Y, Seki T, Fujita J, Yuasa S, Tohyama S, Kunitomi A, Tabei R, Nakajima K, Okada M, Hirano A, Kanazawa H, Fukuda K.	Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.	PLoS One.	9(5)	e97397
Seki T, Fukuda K.	Methods of induced pluripotent stem cells for clinical application.	World J Stem Cells.	7(1)	116-125

IV. 研究成果の刊行物・別刷



Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing Neprilysin-2



Koutaro Takamatsu^{a,b,c,*}, Tokunori Ikeda^{a,b,c}, Miwa Haruta^{a,c}, Keiko Matsumura^{a,c}, Yasuhiro Ogi^b, Naomi Nakagata^d, Makoto Uchino^e, Yukio Ando^b, Yasuharu Nishimura^a, Satoru Senju^{a,c}

^a Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

^b Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

^c CREST, Japan Science and Technology Agency, Kawaguchi, Japan

^d Division of Reproductive Engineering, Center for Animal Resources and Development, Kumamoto University, Kumamoto, Japan

^e Department of Neurology, Jonan Hospital, Kumamoto, Japan

Received 21 September 2013; received in revised form 17 September 2014; accepted 1 October 2014
Available online 12 October 2014

Abstract The purpose of this study was to evaluate the therapeutic potential of human induced pluripotent stem (iPS) cell-derived macrophage-like cells for Alzheimer's disease (AD). In previous studies, we established the technology to generate macrophage-like myeloid lineage cells with proliferating capacity from human iPS cells, and we designated the cells iPS-ML. iPS-ML reduced the level of A β added into the culture medium, and the culture supernatant of iPS-ML alleviated the neurotoxicity of A β . We generated iPS-ML expressing the Fc-receptor-fused form of a single chain antibody specific to A β . In addition, we made iPS-ML expressing Neprilysin-2 (NEP2), which is a protease with A β -degrading activity. In vitro, expression of NEP2 but not anti-A β scFv enhanced the effect to reduce the level of soluble A β oligomer in the culture medium and to alleviate the neurotoxicity of A β . To analyze the effect of iPS-ML expressing NEP2 (iPS-ML/NEP2) in vivo, we intracerebrally administered the iPS-ML/NEP2 to 5XFAD mice, which is a mouse model of AD. We observed significant reduction in the level of A β in the brain interstitial fluid following administration of iPS-ML/NEP2. These results suggested that iPS-ML/NEP2 may be a potential therapeutic agent in the treatment of AD.

© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license (<http://creativecommons.org/licenses/by-nc-sa/4.0/>).

Abbreviations: iPS cells, induced pluripotent stem cells; AD, Alzheimer's disease; A β , β amyloid peptide; A β O, β amyloid peptide oligomer; iPS-ML, iPS cell-derived macrophage-like myeloid lineage cells; NEP2, Neprilysin-2; scFv, single chain antibody; MMEL, Membrane metallo-endopeptidase-like protein; ISF, interstitial fluid; iPS-MC, iPS cell-derived myeloid cells; APP, amyloid precursor protein; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage-colony-stimulating factor.

* Corresponding author at: Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Honjo 1-1-1, Kumamoto 860-8556, Japan. Fax: +81 96 373 5895.

E-mail address: taktr@fc.kuh.kumamoto-u.ac.jp (K. Takamatsu).

<http://dx.doi.org/10.1016/j.scr.2014.10.001>

1873-5061/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license (<http://creativecommons.org/licenses/by-nc-sa/4.0/>).

Introduction

Alzheimer's disease (AD) is the most common cause of neurodegenerative dementia in elderly people; currently, the disease affects more than 36 million people worldwide. AD is characterized by slowly progressive recent memory deficits, cognitive impairment, and personality changes associated with neuronal loss (Blennow et al., 2006). The main risk factor of sporadic AD is aging; prevalence after 65 years of age is 5%, increasing to about 30% of people aged over 85 years old. As a result of the prolonged lifespans in our aging society, the number of patients is expected to continue to increase in the future (Ferri et al., 2005). At the moment, only symptomatic therapies for this disease are available, and the development of a disease-modifying therapy is a required (Carter et al., 2010).

The two major pathological hallmarks of AD are extracellular senile plaques and intraneuronal neurofibrillary tangles. Senile plaques mainly consist of β amyloid peptide (A β), especially the A β 1–42 isoform. Based on the genetic findings from familial AD studies, A β is assumed to be the primary inducer of AD pathology (Hardy and Selkoe, 2002; Tanzi and Bertram, 2005). Transgenic mouse lines that accumulate A β in their brains are used as experimental models to identify a therapeutic approach for AD. Previous studies have shown that vaccination reduced the brain A β deposits and improved cognitive functions in these model animals (Janus et al., 2000; Morgan et al., 2000; Schenk et al., 1999). Nevertheless, in the human clinical trials, vaccination therapy has failed to improve cognitive function so far (Robinson et al., 2004). Furthermore, several adverse events such as meningo-encephalitis (Nicoll et al., 2003), vasogenic edema (Salloway et al., 2009), and micro hemorrhage (Boche et al., 2008) occurred in some of the treated patients.

Inflammatory changes are observed in AD brains, particularly at the vicinity of senile plaques. They are abundant in activated microglia, which are the resident macrophages in the central nervous system, in both human AD samples (Mattiace et al., 1990; Perlmutter et al., 1990) and transgenic mouse models (Frautschy et al., 1998). A β -activated microglia release a wide variety of neurotoxic molecules including proinflammatory cytokines (Griffin, 2006), reactive oxygen species (Reddy et al., 2009), and complement proteins (Bonifati and Kishore, 2007), which contribute to the neurodegeneration in AD. On the other hand, microglia have beneficial effects against AD as a result of neurotrophic agent secretion and clearing A β by phagocytosis (Mizuno et al., 2004; Yan et al., 2006). In addition, *in vitro* experiments strongly suggest a role for microglia in phagocytic clearance of A β . Phagocytosis of A β by exogenously administered microglia was indicated by an *in vivo* study using intra-hippocampal A β -injected rats (Takata et al., 2007). However, their exact role in the pathogenesis of AD remains to be elucidated.

Macrophages are innate immune cells with the capacity to eliminate invading pathogens and dying cells, and maintain homeostasis in many tissues. Manipulation of macrophages to enhance their capacity to efficiently clear A β with low neurotoxicity is expected to provide therapeutic treatments for AD (Malm et al., 2010). A recent study demonstrated that peripherally transplanted CD11b⁺ bone marrow-derived monocytes (BMM) migrate into the vicinity of A β plaques, and that these modified cells secreted the

proteolytic enzyme neprilysin and reduced the A β burden in model mice (Lebson et al., 2010).

These results suggest the potential of bone marrow-derived myeloid-lineage cells in alleviating AD pathology and as therapeutic agents. However, to use myeloid-lineage cells in AD therapy, an adequate supply of therapeutic cells is necessary. Preparation of a large quantity of myeloid lineage cells from bone marrow or peripheral blood of AD patients for the treatment is not practical and the limited cellular sources obstruct the development of a cell-based therapy. Recently, we have developed an iPS cell-based method to generate abundant quantities of myeloid lineage cells. Using this technology, it may be possible to resolve the issue of limited cell sources (Senju et al., 2009). Previously, we have reported the generation of iPS cell-derived macrophage-like myeloid lineage cells (iPS-MC) that were genetically modified to express a membrane-bound form of single chain antibody (scFv) specific to A β . In the *in vitro* analysis, the A β -specific scFv-transfected iPS-MC exhibited efficient A β -specific phagocytic activity (Senju et al., 2011).

Neprilysin is a membrane-bound protease with efficient A β degradation activity (Iwata et al., 2001). The amino acid sequence of membrane metallo-endopeptidase-like protein (MME1, neprilysin-2) has been reported to be highly homologous with neprilysin. Neprilysin-2 (NEP2) has two alternatively spliced forms: a membrane-bound and soluble-secreted variant. The soluble-secreted form is also known as soluble, secreted endopeptidase (SEP) (Ikeda et al., 1999). In mice, Nep2 is expressed in testis and involved in sperm function, as well as modulating fertilization and early embryonic development (Ghaddar et al., 2000). NEP2 has also been characterized in the human brain, and a recent study reported that NEP2 activity is reduced in mild cognitive impaired patients and AD patients (Huang et al., 2012). Also Hafez and colleagues have demonstrated using gene knockout and transgenic animals that NEP2 contributes to A β degradation *in vivo* (Hafez et al., 2011).

In this study, we genetically modified macrophage-like myeloid lineage cells with proliferating capacity generated from human iPS cells (iPS-ML) (Haruta et al., 2013; Koba et al., 2013) to express the A β -degrading protease NEP2. *In vitro*, the transfected macrophages secreted NEP2 and reduced the levels of A β 1–42 oligomers in the culture medium. In addition, they protected co-cultured SH-SY5Y neuroblastoma cells from the toxicity of A β 1–42 oligomers. To evaluate the potential for AD therapy, we examined whether iPS-ML could lower the levels of A β 1–42 peptide in brain interstitial fluid (ISF) in AD model mice. To this end, we set up a microdialysis-based ISF sampling system to examine the level of soluble A β 1–42 peptide in the mouse brain ISF. Administration of NEP2-secreting iPS-ML into the hippocampus of the AD model transgenic mice diminished A β 1–42 in the ISF, thereby suggesting the possibility of NEP2-secreting iPS-ML as a therapeutic means for AD.

Materials and methods

Cells and antibodies

All experiments using human samples were conducted with the approval of the Institutional Review Board of Kumamoto

University. Human iPS cells were previously established by lentivirus-mediated introduction of reprogramming factors into fibroblasts and maintained as previously described (Senju et al., 2011). The following mAbs conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE) were purchased from BD Pharmingen (San Diego, CA), Beckman Coulter (Brea, CA), Miltenyi Biotec (Bergish-Gladbach, Germany), Sigma-Aldrich (St. Louis, MO), or eBioscience (San Diego, CA): anti-CD45 (clone HI30, mouse IgG1), anti-CD33 (WM53, mouse IgG1), anti-CD36 (FA6.152, mouse IgG1), anti-CD11b (ICRF44, mouse IgG1), anti-CD13 (WM15, mouse IgG1), anti-CD87 (62022, mouse IgG1). For isotype-matched controls, mouse IgG1 (MOPC-21) was used.

Plasmid construction and generation of recombinant lentivirus

A cDNA fragment of human cMYC was obtained by PCR and cloned into the pENTR-TOPO vector (Invitrogen, Carlsbad, CA, USA). cDNAs of human EZH2, NEP-2, BMI1, and MDM2 were provided by RIKEN BioResource Center (Tsukuba, Japan) or NRBC (Tokyo, Japan). The A β -specific scFv construct was reported previously (Senju et al., 2011). The cDNA fragments were transferred to a lentiviral expression vector, pCSII-EF (Miyoshi et al., 1998) or pCSII-EF/IRES-NEO, by using the LR clonase system (Invitrogen). pCSII-EF and the plasmids for lentiviral vector packaging, pCMV-VSV-G-RSV-Rev and pCAG-HIVgp, were kindly provided by Dr H. Miyoshi (RIKEN BioResource Center). Plasmid constructs were introduced into 293T cells by using lipofection (Lipofectamine 2000, Invitrogen), and recombinant lentivirus was recovered from the culture supernatant by centrifugation (50,000 g, 2 h) 3 days later.

Generation of human iPS cell-derived proliferating myeloid cells

Two lines of human iPS cells were used in this study; one (iPSL) was established from skin fibroblasts by using lenti virus-mediated introduction of reprogramming factors (Senju et al., 2011) and the other (iPSS) was established from peripheral blood T cells by using sendai virus-mediated introduction of reprogramming factors (Cytotune, Dnavec, Tsukuba, Japan). iPS cells were induced to differentiate into myeloid cells (iPS-MC) according to a previously established procedure (Senju et al., 2011). To establish iPS-ML (Haruta et al., 2013; Koba et al., 2013), iPS-MC derived from iPSL were introduced with expression vectors for cMYC plus EZH2 (iPS-ML-A) and iPS-MC derived from iPSS were introduced with cMYC, BMI1, plus MDM2 (iPS-ML-B). Both iPS-ML were cultured in the presence of M-CSF (50 ng/mL) and GM-CSF (50 ng/mL). To generate NEP-2-transfectant, the iPS-ML were infected with the recombinant lentivirus vector including IRES-Neomycin-resistance cassette for NEP2 and cultured in the presence of G-418 to select iPS-ML stably expressing NEP2.

Flow cytometric analysis

The cell samples were treated with human Fc-receptor-blocking reagent (Miltenyi Biotec) for 10 min, stained with

the fluorochrome-conjugated mAb for 30 min, and washed 3 times with phosphate-buffered saline/2% fetal calf serum. The stained cell samples were analyzed using a FACScan flow cytometer (BD Bioscience, Bedford, MA, USA). For detection of cell surface NEP2, cells were incubated with polyclonal goat anti-human NEP2 antibody (AF2340; R&D Systems) for 30 min at 4 °C and with anti-goat IgG FITC (secondary antibody) for 30 min at 4 °C. For intracellular staining of NEP2, iPS-ML were fixed and permeabilized using IntraPrep reagent (Beckman Coulter), and stained with a polyclonal NEP2 antibody as described above. Goat IgG was also used as control. The cell samples were analyzed using a FACScan flow cytometer.

Western blot analysis

After the iPS-ML were cultured for 24 h, they were centrifuged and separated into cell pellets and culture supernatants. The cell pellets were subjected to protein extraction by using CytoBuster™ Protein Extraction Reagent (Novagen, San Diego, CA, USA). Protein concentration was determined using a BCA protein assay kit (PIERCE, Rockford, IL, USA). After determination of protein concentration, sample buffer containing 2-mercaptoethanol was added to the culture supernatants and cell-extracts. Samples of supernatants and cell-extracts were subjected to SDS-PAGE on 4–20% TGX Protean® gels (Bio-Rad, Hercules, CA, USA) by using a Mini Protean® II Electrophoresis Cell (Bio-Rad), and electronically transferred onto Immobilon-Blot® PVDF membranes (Bio-Rad) using a Mini Trans-Blot® Cell (Bio-Rad) at 100 mA for 1 h. After blocking overnight in Tris-buffered saline (0.1 M Tris-HCl, 0.9% NaCl, pH 7.4) containing 0.1% Tween 20 and 5% skim milk at 4 °C, the blots were incubated with NEP2-specific polyclonal antibody for 1 h and subsequently with an anti-goat horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h. As a control for equal protein loading in the analysis of cell extracts, membranes were also probed with a mouse anti- β -actin antibody (Sigma-Aldrich) and exposed to an HRP-conjugated anti-mouse antibody. Signals were visualized using ECL plus (Amersham Pharmacia Biotech, Buckinghamshire, UK) reagents and detected by a FPM100 developer (Fujifilm, Tokyo, Japan). All procedures were performed at room temperature unless otherwise stated.

Preparation of A β oligomers

Soluble A β 1–42 oligomer (A β O) solutions were prepared as previously described (Stine et al., 2003). Briefly, synthetic human A β 1–42 (Peptide Institute, Osaka, Japan) was dissolved at 1 mM in cold 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP). The peptide was incubated at room temperature for 2 h to ensure it was monomeric and unstructured. The HFIP was dried by the vacuum desiccator and the resulting peptide film was stored at –20 °C until use. To form oligomers, the film of A β was dissolved in DMSO at 5 mM and further diluted to 100 μ M in phenol red-free F12 medium (Ham's F-12, BioSource) by vortexing for 10 min. Subsequently, the solution was aged for 24 h at 4–8 °C. The sample was then centrifuged at 15,000 g for 10 min at 4–8 °C, and the soluble oligomers remained in the supernatant.

Analysis of A β O degradation in vitro

iPS-ML were cultured for 24 h and the culture supernatants were collected. iPS-ML (1×10^5 /well in 96-well culture plates) or collected supernatants were added with 10 μ M of A β O in the presence or absence of 10 μ M phosphoramidon (Sigma-Aldrich). After 24 h of incubation at 37 °C (5% CO₂), the culture medium was centrifuged to remove cell debris (1500 g, 10 min, 4 °C). The amount of A β 1–42 in the resultant supernatants was quantified using an A β 42-specific ELISA kit (Wako Chemicals, Tokyo, Japan). Statistical analysis was performed using two-tailed Student's *t*-tests and comparison with the control (without iPS-ML).

Analysis of A β O cytotoxicity

SH-SY5Y neuroblastoma cells were plated at a density of 1×10^4 cells/well in 96-well plates in DMEM/F12 (1:1) medium supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin and 100 μ g/mL streptomycin, and incubated for 24 h at 37 °C in 5% CO₂. After incubation for 24 h, the medium was replaced with serum-free DMEM/F12 (1:1) medium containing the A β O solution. The cells were incubated for 48 h and the number of live cells was analyzed using the CellTiter 96 assay kit (Promega, Madison, WI) according to the kit protocol. Briefly, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2 H-tetrazolium, inner salt (MTS) was added to culture plates and the plates were incubated at 37 °C for 3 h. Absorbance at 490 nm was measured to quantify the number of live cells. The results are expressed as the percentage of MTS reduced relative to the control samples, assuming the absorbance of the control cells was 100%. To analyze the effect of iPS-ML on the death of SH-SY5Y cells, culture supernatants were prepared from iPS-ML cultured at a density of 2.5×10^5 cells/mL for 24 h. SH-SY5Y cells were plated at a density of 1×10^4 cells per well in 96-well plates ($n = 3$ wells in each experimental condition). After 24 h, the culture medium from the SH-SY5Y cells was replaced with the culture supernatant from the iPS-ML and A β O and/or the NEP-2 inhibitor phosphoramidon. After 48 h of incubation, the number of live SH-SY5Y cells was quantified using the CellTiter 96 assay kit, as described above.

Generation of scid/5XFAD mice

5XFAD mice (Oakley et al., 2006) harbor three mutations in the amyloid precursor protein (APP) gene and two in the presenilin-1 (PS1) gene and were used for in vivo analysis. These mice increase soluble A β production, develop senile plaques by 4 to 5 weeks of age, and show neuronal damage including intraneuronal accumulation of A β and cognitive deficits by 5 months. 5XFAD mice were crossed to scid mice, and hemizygous 5XFAD transgenic mice with scid/scid genetic backgrounds were used in the experiments.

In vivo microdialysis and iPS-ML transplantation

To measure the levels of soluble A β 1–42 in the hippocampus ISF of awake, freely moving 5XFAD mice, microdialysis was performed as previously described (Takeda et al., 2011) with some modifications. Probe implantation was performed as

previously described (Cirrito et al., 2003). Briefly, the animals were anesthetized with sodium pentobarbital (intraperitoneal injection, 50 mg/kg; Dainippon Sumitomo Pharma, Osaka, Japan), while a guide cannula (8 mm length) was stereotaxically implanted in the right hippocampus (bregma 3.1 mm, 2.4 mm lateral to the midline, and 1.1 mm ventral to dura at a 12° angle). The guide cannula was fixed using an anchoring bone screw and binary dental cement. More than 3 days after guide cannula implantation, the mice were placed in a standard microdialysis cage and a probe was inserted through the guide. The microdialysis probe had an 8 mm shaft with a 4 mm, 1000 kDa molecular weight cutoff polyethylene membrane (PEP-8-04, Eicom, Kyoto, Japan). Before use, the probe was conditioned by brief dipping in ethanol, and then washed with perfusion buffer (0.15% bovine serum albumin in Ringer's solution) that was filtered through a 0.22 μ m pore size membrane (GL Sciences Inc., Japan). The preconditioned probe's outlet and inlet were connected to a peristaltic pump (Eicom) and microsyringe pump (Eicom), respectively, using fluorinated ethylene propylene (FEP) tubing (ϕ 250 μ m i.d.). After insertion of the probe, to obtain a stable 2 h of baseline recordings, the probe and connecting tubes were perfused with the perfusion buffer for 180 min at a flow rate of 10 μ L/min before the baseline sample collection. The flow rate was maintained at 1.0 μ L/min with a peristaltic pump (Eicom) and microsyringe pump (Eicom).

Samples were stored at 4 °C for less than 24 h in a polypropylene tube before being subjected to ELISA testing. Samples were denatured with 500 mM guanidine HCl, which solubilizes aggregated A β , and the A β 1–42 levels were measured using a sandwich ELISA kit (Wako Chemicals). Baseline levels of ISF A β 1–42 were defined as the mean concentration of A β over the 2 h preceding IPS-ML transplantation or Ringer's solution injection. For each animal, all A β levels were normalized to the basal A β concentration.

For iPS-ML transplantation into the hippocampus, microdialysis probes with a separate injection port at the tip (PEP-8-04-MI, Eicom) were used. This permitted us to perform microdialysis and still administer iPS-ML to the hippocampus. IPS-ML were preloaded into a 10 μ L Hamilton syringe and connected to the infusion port of the microdialysis probe with FEP tubing. The iPS-ML suspended in Ringer's solution (5×10^7 /mL) were injected into the hippocampus 3 μ L for 3 min.

Histological analysis

iPS-ML labeled with PKH26 (Sigma-Aldrich) or introduced with GFP-expression vector were injected into the hippocampus of mice as described above. For microscopic examination, the brain tissue was removed, fixed in 4% paraformaldehyde/phosphate-buffered saline, and embedded in Tissue-TEK OCT compound (Sakura Finetechnical, Tokyo, Japan). Frozen sections of 20- μ m thickness were made using a cryostat (MICROM HN505N; Thermo Scientific, Kalamazoo, MI). The tissue sections were stained with Congo red to detect amyloid plaques, or stained with DAPI and analyzed using fluorescence microscopes (Axio Observer Z1, Carl Zeiss, Oberkochen, Germany. and FV1200, Olympus, Tokyo, Japan).

Results

Generation of iPS-ML expressing Nephilysin-2

We previously established a method to generate CD43⁺CD11b⁺ myeloid-lineage cells from human iPS cells, and designated them iPS-MC (iPS cell-derived myeloid-lineage cells) (Senju et al., 2011). iPS-MC proliferated in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage-colony-stimulating factor (M-CSF) for 7–14 days, and then stopped proliferating. The generation of iPS-MC with long-term proliferation would be a beneficial source of large amounts of macrophages for cell-based therapies. We had found that simultaneous introduction of cMYC in combination with EZH2, BMI1, or MDM2 resulted in the prolonged proliferation of iPS-MC. The cells continuously propagated for more than 3 months in the presence of M-CSF, with a doubling time of 24–36 h. Based on the observation, we established a method to generate a large quantity of human myeloid lineage cells. We named the iPS cell-derived long-term proliferating myeloid cells iPS-ML (iPS cell-derived myeloid cell line) (Haruta et al., 2013; Koba et al., 2013). Morphology and hematopoietic and myeloid markers, such as CD45, CD36, CD11b, CD13, CD87, and CD33 of iPS-ML generated by introduction of cMYC plus EZH2 (iPS-ML-A) and those generated by introduction of cMYC, BMI1, plus MDM2 (iPS-ML-B) into iPS-MC are shown in Fig. 1. A growth curve and results of chromosomal analysis of iPS-ML-B are shown in Supplemental Fig. 1.

iPS-ML with A β -degrading activity could be useful for therapy of AD. We generated an iPS-ML expressing a protease with A β -degrading activity. Nephilysin (NEP) is a well-known A β -degrading zinc-dependent metalloprotease (Iwata et al., 2001). NEP is a membrane-bound protease, and we considered that, rather than using a membrane-bound protease, a secreted type of the protease would be more appropriate and effective to degrade extracellular A β oligomers (A β O). Membrane metallo-endopeptidase-like protein (MMEL, NEP2), expressed as both membrane-bound protein and secreted protein, has also A β -degrading activity (Hafez et al., 2011).

To generate NEP2-expressing iPS-ML, we introduced a NEP2-expression vector into the iPS-ML-A by lentivirus-mediated transduction. Flow cytometric analysis of the NEP2-transfectant iPS-ML-A (iPS-ML-A/NEP2) detected NEP2 both on the cell surface and within the cells (Fig. 2A). Western blot analysis detected the NEP2 protein in both the cell lysate and the culture supernatant of the iPS-ML-A/NEP2 (Fig. 2B). These results indicate that the iPS-ML-A/NEP2 expressed NEP2 on the cell surface and also secreted NEP2 into the culture medium.

NEP-2-expressing iPS-ML and culture supernatants degrade A β 42 oligomers

To examine the ability of iPS-ML to reduce A β O, we added A β O to the culture of non-transfected iPS-ML-A, anti-A β -scFv (Senju et al., 2011)-transfected iPS-ML-A (iPS-ML-A/scFvA β), and iPS-ML-A/NEP2. After 24 h of incubation, the culture supernatant was collected and A β O in the supernatant was quantified by ELISA. In Fig. 3A, data are presented as the percentage of A β O remaining compared to a control condition

(without iPS-ML). The results indicate that even non-transfected iPS-ML-A had a reducing effect on the level of A β O in the culture medium by about 30%. The effect of iPS-ML-A/scFvA β was similar to that of the non-transfected iPS-ML-A, thereby indicating that expression of anti-A β -scFv did not enhance the A β O-reducing effect. In contrast, the iPS-ML-A/NEP2 showed a much more potent effect to reduce A β O (about 90% reduction) as compared with the non-transfected iPS-ML-A. The enhanced A β O-reducing activity gained by the expression of NEP2 was almost totally canceled by the presence of phosphoramidon, which is a protease inhibitor known to inhibit the activity of NEP2.

We also analyzed the A β O-reducing activity of the culture supernatant of iPS-ML-A, iPS-ML-A/scFvA β , and iPS-ML-A/NEP2. As shown in Fig. 3B, the culture supernatant of the iPS-ML-A and iPS-ML-A/scFvA β did not reduce the level of A β O, thereby suggesting that the reduction of A β O by the non-transfected iPS-ML-A and iPS-ML-A/scFv A β (Fig. 3A) was mediated by the endocytosis of A β O by iPS-ML-A or by effect of some membrane-associated proteases other than NEP2. The culture supernatant of the iPS-ML-A/NEP2 reduced the level of A β O by about 50%, and the effect was abolished by the presence of phosphoramidon.

Thus, both the iPS-ML-A/NEP2 and its culture supernatant reduced the level of A β O. On the other hand, non-transfected iPS-ML-A and iPS-ML-A/scFv A β , but not their culture supernatants, reduced the level of A β O. A previous study reported that only the NEP2 β splice form of human NEP2, which is located at the cell surface, degrades A β (Huang et al., 2008). The results of our experiments demonstrated that the secreted form of NEP2 also degrades A β O.

To confirm the reproducibility of the results described above, we repeated the experiments using a different iPS-ML (iPS-ML-B), which had been generated by introduction of cMYC, BMI1, plus MDM2 as proliferation factors. As shown in Supplementary Fig. 2, iPS-ML-B also reduced the level of A β O in the culture medium. NEP2-transfectant iPS-ML-B (iPS-ML-B/NEP2) exhibited higher activity to reduce A β O in the culture medium than non-transfectant iPS-ML-B (Supplementary Fig. 2).

Taken together, iPS-ML could reduce the level of A β O in the culture supernatant, and the effect was enhanced by the forced expression of NEP2. In addition, NEP2 secreted from NEP2-transfectant iPS-ML also reduced A β O in the culture supernatant.

NEP2-expressing iPS-ML attenuates the neurotoxicity induced by A β 42 oligomers

Microglia could exacerbate the pathogenesis of AD by accelerating neuronal loss and cognitive deficits through the production of neurotoxic pro-inflammatory cytokines such as interleukin1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF- α) (Griffin, 2006). Although reduction of A β O by iPS-ML may inhibit disease progress, if it comes at the cost of increased neurotoxicity, then it is doubtful whether treatment with iPS-ML is beneficial for the AD patients.

We investigated whether culture supernatants of iPS-ML exacerbate or alleviate the neurotoxic effect of A β O. Toxicity of A β O on the SH-SY5Y neuroblastoma cell line was assessed by a modified MTT reduction assay, utilizing a




Figure 1 Morphology and cell surface molecules of iPS cell-derived myeloid cell line (iPS-ML). A. Phase contrast images of iPS cell-derived myeloid cell line (iPS-ML-A and iPS-ML-B) in culture plate are shown. B. Expression of CD45, CD36, CD11b, CD13, CD87, and CD33 on iPS-ML was analyzed by flow cytometry. Staining profiles of the specific monoclonal antibody (mAb; thick lines) and an isotype-matched control mAb (gray area) are shown.

tetrazolium compound (MTS). Incubation in the presence of more than 5 μ M A β O to SH-SY5Y cell cultures resulted in significant cell death (Fig. 4A).

Culture supernatant of non-transfected iPS-ML-A reduced the toxicity of A β O against SH-SY5Y cells (Fig. 4B). As shown in Fig. 3B, culture supernatant of non-transfected iPS-ML-A did not reduce the level of A β O. Therefore, the observed inhibition of death in the SH-SY5Y cells was not mediated by the reduction of A β O. Probably, iPS-ML produced some soluble factors that protect the SH-SY5Y cells from death. Culture supernatant of iPS-ML-A/NEP2 reduced the neurotoxicity more efficiently than that of non-transfected iPS-ML-A (Fig. 4B). Addition of phosphoramidon to the supernatant of iPS-ML-A/NEP2 abolished most of the effect of NEP2-transgene. Culture supernatant of iPS-ML-B also protected SH-SY5Y cells from toxic effect of A β O (Fig. 4C). The neuroprotective effect of culture supernatant of iPS-ML-B was also enhanced by forced expression of NEP2 (Fig. 4C).

Taken together, these results demonstrate that iPS-ML produced some soluble neuroprotective factor that protected SH-SY5Y cells from A β O-induced death. In addition, NEP2 secreted by NEP2-transfectant iPS-ML further reduced the toxicity of A β O by decreasing the level of A β O.

Intrahippocampally transplanted NEP-2-expressing human iPS-MP reduces brain ISF A β in 5XFAD mice

We examined the effect of iPS-ML-A/NEP2 on A β O levels in vivo. To this end, we used 5XFAD mice, which accumulate A β in their brain tissue that is observable from 2 months of age. We planned to intrahippocampally administrate iPS-ML-A/NEP2 into 5XFAD mice and examine whether it resulted in reduction of A β O in the brain tissue. To avoid the immune-mediated rejection of transferred cells and accompanying inflammation, we crossed 5XFAD mice to immune-compromised SCID mice and establish 5XFAD mice with scid/scid genetic backgrounds (5XFAD/scid mice).

Continuous sampling of ISF by microdialysis was done to assess the dynamic change of soluble A β in awake, free-moving animals. To this end, we inserted the microdialysis probe with a microinjection tube into the right hippocampus of 3–4-month old 5XFAD/scid male mice. To confirm proper administration of iPS-ML into the hippocampus, we injected fluorescent dye (PKH26)-labeled iPS-ML-A or GFP-expressing iPS-ML-B, and histologically analyzed the hippocampus. Staining of the tissue sections with Congo red visualized the amyloid plaques in the hippocampus (Fig. 5A). Migration of iPS-ML into a region adjacent the microinjection




Figure 2 Expression of NEP2 by NEP2-expressing iPS-ML. **A**, Flow cytometric analysis of the cell surface and intracellular expression of NEP2 in NEP2-expressing iPS-ML (iPS-ML-A/NEP2). The staining profiles of the specific monoclonal antibodies (mAb; thick lines) and an isotype-matched control mAb (gray area) are shown. **B**, Cell extracts and culture supernatants of non-transfected iPS-ML-A and iPS-ML-A/NEP2 were subjected to western blot analysis to detect NEP2 protein. Recombinant human NEP2/MMEL was used as a positive control. β-actin was also probed for equal loading of cell extracts.

tube insertion site was revealed by fluorescence microscopy (Figs. 5B and C).

After 2 h of baseline sampling, iPS-ML-A, iPS-ML-A/NEP2 or Ringer’s solution as control were injected into the right hippocampus via the microinjection tube. Basal levels of brain ISF Aβ1–42 were defined as their mean concentration over 2 h preceding iPS-ML administration. The effect of iPS-ML transfer was assessed by measuring the level of Aβ1–42 in the ISF obtained by microdialysis after 9 h of the

iPS-ML injection. For each animal, the Aβ1–42 concentration was normalized to the basal level.

As shown in Fig. 6, the administration of iPS-ML-A/NEP2 resulted in decreased Aβ1–42 concentrations in the ISF by more than 40% as compared with the basal level. The level of Aβ1–42 in ISF of the mice treated with the iPS-ML-A/NEP2 was significantly lower than that of the mice treated with non-transfected iPS-ML-A or Ringer’s solution. These results indicate that intracerebral administration of iPS-ML/NEP2




Figure 3 Reduction of Aβ levels in culture medium by NEP2-expressing iPS-ML. **A**, Non-transfected iPS-ML-A, single chain Aβ antibody-expressing iPS-ML-A (iPS-ML-A/scFv Aβ), or NEP2-expressing iPS-ML-A (iPS-ML-A/NEP2) were cultured in medium containing Aβ oligomers (AβO) in the presence or absence of phosphoramidon. After culture for 24 h, culture supernatants were recovered and the Aβ1–42 concentration was analyzed by ELISA. **B**, Non-transfected iPS-ML-A, iPS-ML-A/scFv Aβ, or iPS-ML-A/NEP2 were cultured for 24 h, and the culture supernatants was recovered. Subsequently, AβO was added to the culture supernatant and incubated at 37 °C in the presence or absence of phosphoramidon. After incubation for 24 h, the concentration of Aβ42 was determined by ELISA. Mean values + standard error of the mean (n = 3–6) relative to no iPS-ML control (Control) are shown; *P < 0.05, **P < 0.005, *** P < 0.001.




Figure 4 Inhibition of A β oligomer-induced neuronal cell death by NEP2-expressing iPS-ML in vitro. **A.** SH-SY5Y neuroblastoma cells were cultured (1×10^4 cells/100 μ L/well in 96-well plates) in the presence of the indicated concentrations of A β oligomers (A β O). After 48 h, the number of live cells was analyzed by MTS assay. Data are presented as relative number of cells where the value for culture of the cells without A β O was defined as 100%, and the mean value + standard error for triplicate cultures are shown. ($n = 3$, $*P < 0.001$). **B.** Culture supernatants of iPS-ML-A and NEP2-expressing iPS-ML-A (iPS-ML-A/NEP2) were prepared as in Fig. 3B. SH-SY5Y neuroblastoma cells were cultured (1×10^4 cells/100 μ L/well in 96-well plates) in the presence of A β (10 μ M), and the prepared iPS-ML culture supernatants were added with or without phosphoramidon (10 μ M). After 48 h, the number of live SH-SY5Y cells was analyzed by MTS assay. Data are presented as relative number of cells where the number in the culture in the absence of A β was defined as 100%, and means + standard error for triplicate cultures are shown. ($n = 3$, $*P < 0.005$, $**P < 0.001$). **C.** Culture supernatant of monocyte-derived macrophages (CD14 $^+$ MP), iPS cell derived without proliferating capacity (iPS-MC), iPS-ML-B, or NEP2-expressing iPS-ML-B (iPS-ML-B/NEP2) was added to SH-SY5Y cells in the presence of A β (10 μ M). After 48 h, the number of live SH-SY5Y cells was analyzed by MTS assay. Data are presented as relative number of cells where the number in the culture in the absence of A β was defined as 100%, and means + standard error for triplicate cultures are shown. ($n = 3$, $*P < 0.05$, $**P < 0.01$, $***P < 0.001$).

reduced the concentration of A β 1–42 in the ISF by degradation of A β 1–42 by transgene-derived NEP2.

Discussion

Microglia are resident immune cells in the CNS that regulate innate immunity and participate in adaptive immune response (Hanisch and Kettenmann, 2007). However, the roles of microglia in AD pathology are still under debate. While there is significant evidence that microglial activation initiates and advances AD pathology, some aspects of

microglia function are proposed to be beneficial because microglia are able to reduce A β deposition by phagocytosis (Gentleman, 2013). In animal models of AD, it has been reported that deficient microglial phagocytic activity accelerates pathology progression (El Khoury et al., 2007; Hickman et al., 2008), whereas exogenous transplantation of microglia enabled the clearance of A β depositions (Takata et al., 2007). Results from clinical trials of A β peptide vaccination have suggested microglial phagocytic clearance of A β from the cortex (Zotova et al., 2011).

In mouse models of AD, bone marrow-derived cells have been shown to reduce the A β burden (Lee et al., 2010).

Furthermore, several groups have recently reported that bone marrow-derived cells are able to differentiate into functional microglia (BMDM) and the therapeutic effect of BMDM in $A\beta$ clearance is also suggested (Magga et al., 2012). Therefore, bone marrow cells may be an appropriate source of microglial progenitors for clinical application. Nevertheless, the repetitive administration requires a large quantity of cells. Therefore, to develop a cell-based therapy, it is necessary to resolve the issue of cell source. We have previously established a method to generate a large quantity of macrophage-like myeloid cells (Haruta et al., 2013; Koba et al., 2013; Senju et al., 2011). Cell-based therapy with iPS-ML may be one of the promising candidates for future therapeutic treatments.

Lentiviral modification of hematopoietic stem cells provided clinical benefits in an X-linked adrenoleukodystrophy (Cartier et al., 2009). iPS-ML could also be modified by the lentivirus vector to produce long-term transgene expression without compromising cell proliferation or function. We generated iPS-MC expressing a Fc-receptor-fused form of the $A\beta$ -specific single chain antibody (scFv). Phagocytosis of $A\beta$ -coated microbeads by iPS-MC was significantly enhanced by the expression of the anti- $A\beta$ scFv (Senju et al., 2011). Recent studies revealed that soluble oligomeric $A\beta$ ($A\beta$ O) is the most neurotoxic $A\beta$ species (Lambert et al., 1998; Walsh et al., 2002; Zahs and Ashe, 2013). Therefore, in the current study, we examined whether iPS-ML could reduce the level of $A\beta$ O in the culture




Figure 6 Degradation of $A\beta$ in brain interstitial fluid of 5XFAD mice by intrahippocampally administrated NEP2-expressing iPS-ML. Microdialysis probes were inserted into the hippocampus of 5XFAD/scid mice to sample the soluble $A\beta$ in the brain interstitial fluid (ISF). Ringer's solution as vehicle control (Control), non-transfected iPS-ML-A, or NEP2-expressing iPS-ML-A (iPS-ML-A/NEP2) were injected into the right hippocampus via the microinjection tubes. Concentrations of $A\beta$ 1–42 in dialysis samples obtained 9 h after the administration of iPS-ML were determined by ELISA. For each mouse, the $A\beta$ 1–42 concentration was normalized to the basal level, which was the mean $A\beta$ 1–42 concentration over the 2 h preceding iPS-ML administration. Data are presented as mean normalized value + standard error of experimental groups ($n = 4$, $*P < 0.05$, $**P < 0.01$).




Figure 5 Intrahippocampal injection of iPS-ML into 5XFAD/scid mice. iPS-ML-A labeled with PKH26 or GFP-expressing iPS-ML-B were injected into the hippocampus of 5XFAD/SCID mice. After 24 h, mice were sacrificed and the brain tissue was removed. A. Frozen sections of 20- μ m thickness were made and stained with Congo red. B. A merged images with blue fluorescence (DAPI) indicating cell nucleus and red fluorescence indicating PKH26-stained iPS-ML-A are shown. C. Merged images with blue fluorescence (DAPI) indicating cell nucleus and green-white fluorescence indicating GFP-expressing iPS-ML-B are shown. The square region in the upper image is magnified in the lower image.

medium (Fig. 3A). Contrary to our expectation, expression of anti-A β scFv in iPS-ML did not enhance the clearance of soluble A β in the culture medium. On the other hand, forced expression of a protease with A β O-degrading activity enhanced the reduction of A β O in the culture medium by iPS-ML. We observed that the iPS-ML highly expressing NEP2 (iPS-ML-A/NEP2), a secretable protease with A β -degrading activity, efficiently reduced A β O (Fig. 3B). In addition, culture supernatant of iPS-ML with or without expression of NEP2 inhibited the A β O-induced death of neuronal cells *in vitro* (Figs. 4B, C). Culture supernatant of iPS-MC, iPS cell-derived myeloid cells without proliferating capacity, also exhibited such effect (Fig. 4C). On the other hand, human peripheral blood monocyte-derived macrophages (CD14⁺ MP) did not exhibit such effect (Fig. 4C).

Microglia act as a source of neurotrophic factors and mitigate neurodegeneration. Microglia-derived neurotrophic factors, such as the brain-derived neurotrophic factor (BDNF), exert well-documented neuroprotective functions (Nagahara et al., 2009). The protection of SH-SY5 cells from A β O-induced death by the culture supernatant of the non-transfected iPS-ML (Figs. 4B, C) may have been mediated by some neurotrophic agents produced by the iPS-ML. Some of soluble factors secreted by CD14⁺MP, iPS-MC, iPS-ML, or NEP2-expressing iPS-ML were examined by bead array system and the results are shown in Supplementary Fig. 3.

To develop an effective cell-based therapy against neurodegenerative disorders of the CNS, efficient recruitment of the cells into the CNS is essential. Previous findings suggest that particular bone marrow derived cells are able to cross the blood–brain barrier (Lebson et al., 2010; Simard and Rivest, 2004). To evaluate the migration of the iPS-ML into the CNS, we examined the effect of intravenous, intraperitoneal, and intracerebroventricular injection of iPS-ML into 5XFAD mice. To our disappointment, the iPS-ML injected via these routes did not efficiently infiltrate into brain parenchyma and failed to reduce the amyloid burden. A possible reason of the failure to efficiently migrate in brain tissue may be the lack of CC chemokine receptor-2 (CCR2) expression in the iPS-ML (data not shown). To analyze the *in vivo* effect of iPS-ML/NEP2, we directly administered iPS-ML into the brain. To this end, we stereotaxically inserted microinjection tubes into the hippocampus of 5XFAD mice and transplanted iPS-ML through this tube. The hippocampus plays a major role in cognitive dysfunction of AD, and the 5XFAD hippocampus is one of the regions of the brain where A β plaques accumulate. iPS-ML transplanted by this procedure migrated to the brain parenchyma adjacent to the area of the tube insertion (Figs. 5B, C).

In vivo, transplantation of iPS-ML/NEP2 into the hippocampus of 3–4-month old 5XFAD/scid mice significantly diminished the levels of soluble A β 1–42 in the brain ISF compared to the control Ringer's solution injection (Fig. 6). The reduction of A β was not significant when non-modified iPS-ML were transplanted. Therefore, the reduction of A β was caused by the secretion of NEP2 from the iPS-ML, but not phagocytosis of A β by the iPS-ML. Our intrahippocampus transplantation of iPS-ML demonstrated short-term and focal remote effects of the iPS-ML; only where the cells were transplanted. Furthermore we could not examine the therapeutic effect of cognitive function, because the mice were weakened by probe implantation. Future studies will be aimed at exploring whether iPS-ML are effective in

preventing cognitive decline and neuronal damage in other AD models. In addition, to develop this technique as a therapy for AD, delivery of iPS-ML into the brain by systemic administration is necessary.

To examine the chromosomal alteration of iPS-ML, iPS-ML cultured for 6 weeks after the introduction of proliferating factors were subjected to karyotype analysis. As shown in Supplemental Fig. S1, some karyotype abnormalities were detected in this analysis. For application of iPS-ML to clinical cellular therapy, we should resolve the issue of genetic instability of iPS-ML. To generate iPS-ML, our current method uses cMYC, BMI1 plus MDM2 to induce proliferation of iPS-MC. Among the introduced factors, MDM2 is involved in degradation of p53 protein as the E3 ubiquitin ligase (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997). Forced expression of MDM2 in iPS-ML may cause complete loss of p53 function and result in the genetic instability of iPS-ML. Although co-introduction of MDM2 enhanced the proliferation rate of iPS-ML, this factor is not absolutely necessary for the establishment of iPS-ML, as previously reported (Haruta et al., 2013; Koba et al., 2013). Omission of MDM2 in the generation of iPS-ML may be one way to improve the genetic stability of iPS-ML.

The risk of tumor occurrence is one of most serious issues to be resolved before the clinical application. We currently use a lentivirus vector to introduce proliferation factors to generate iPS-ML, and administration of such iPS-ML to the patients may cause malignancy. Thus, for the clinical application of iPS-ML-based cellular therapy, a removable vector system should be used to generate iPS-ML.

In addition to AD, many intractable diseases are caused by the accumulation of misfolded proteins. Furthermore, the potential of iPS-ML may involve genetic modification to produce proteolytic enzymes that degrade other deleterious misfolded proteins or prion. We are planning future studies to evaluate the potential of iPS-ML as cell-based therapeutics for neurodegenerative diseases other than AD and various types of amyloidosis.

Acknowledgments

The plasmids used for preparing recombinant lentivirus, pCII-EF, pCMV-VSV-G-RSV-Rev, and pCAG-HIVgp were kindly provided by Dr. H. Miyoshi (RIKEN BioResource Center). cDNAs for human BMI1 and EZH2 were provided by RIKEN BRC which is participating in National Bio-Resources Project of the MEXT, Japan. This work was supported in part by a Grant-in-Aid No. 23659158 from MEXT, Japan, a Research Grant for Intractable Diseases from Ministry of Health and Welfare, Japan, and a grant from Japan Science and Technology Agency (JST).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <http://dx.doi.org/10.1016/j.scr.2014.10.001>.

References

Blennow, K., de Leon, M.J., Zetterberg, H., 2006. Alzheimer's disease. *Lancet* 368, 387–403.

- Boche, D., Zotova, E., Weller, R.O., Love, S., Neal, J.W., Pickering, R.M., Wilkinson, D., Holmes, C., Nicoll, J.A., 2008. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. *Brain* 131, 3299–3310.
- Bonifati, D.M., Kishore, U., 2007. Role of complement in neurodegeneration and neuroinflammation. *Mol. Immunol.* 44, 999–1010.
- Carter, M.D., Simms, G.A., Weaver, D.F., 2010. The development of new therapeutics for Alzheimer's disease. *Clin. Pharmacol. Ther.* 88, 475–486.
- Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrere, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., l'Homme, B., Bougneres, P., Von Kalle, C., Fischer, A., Cavazzana-Calvo, M., Aubourg, P., 2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. *Science* 326, 818–823.
- Cirrito, J.R., May, P.C., O'Dell, M.A., Taylor, J.W., Parsadanian, M., Cramer, J.W., Audia, J.E., Nissen, J.S., Bales, K.R., Paul, S.M., DeMattos, R.B., Holtzman, D.M., 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. *J. Neurosci.* 23, 8844–8853.
- El Khoury, J., Toft, M., Hickman, S.E., Means, T.K., Terada, K., Geula, C., Luster, A.D., 2007. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. *Nat. Med.* 13, 432–438.
- Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K., Hasegawa, K., Hendrie, H., Huang, Y., Jorm, A., Mathers, C., Menezes, P.R., Rimmer, E., Sczufca, M., 2005. Global prevalence of dementia: a Delphi consensus study. *Lancet* 366, 2112–2117.
- Frautschy, S.A., Yang, F., Irrizarry, M., Hyman, B., Saido, T.C., Hsiao, K., Cole, G.M., 1998. Microglial response to amyloid plaques in APPsw transgenic mice. *Am. J. Pathol.* 152, 307–317.
- Gentleman, S.M., 2013. Review: microglia in protein aggregation disorders: friend or foe? *Neuropathol. Appl. Neurobiol.* 39, 45–50.
- Ghaddar, G., Ruchon, A.F., Carpentier, M., Marcinkiewicz, M., Seidah, N.G., Crine, P., Desgroseillers, L., Boileau, G., 2000. Molecular cloning and biochemical characterization of a new mouse testis soluble-zinc-metalloproteinase of the neprilysin family. *Biochem. J.* 347, 419–429.
- Griffin, W.S., 2006. Inflammation and neurodegenerative diseases. *Am. J. Clin. Nutr.* 83, 470S–474S.
- Hafez, D., Huang, J.Y., Huynh, A.M., Valtierra, S., Rockenstein, E., Bruno, A.M., Lu, B., DesGroseillers, L., Masliah, E., Marr, R.A., 2011. Neprilysin-2 is an important beta-amyloid degrading enzyme. *Am. J. Pathol.* 178, 306–312.
- Hanisch, U.K., Kettenmann, H., 2007. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. *Nat. Neurosci.* 10, 1387–1394.
- Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297, 353–356.
- Haruta, M., Tomita, Y., Yuno, A., Matsumura, K., Ikeda, T., Takamatsu, K., Haga, E., Koba, C., Nishimura, Y., Senju, S., 2013. TAP-deficient human iPSC cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. *Gene Ther.* 20, 504–513.
- Haupt, Y., Maya, R., Kazaz, A., Oren, M., 1997. Mdm2 promotes the rapid degradation of p53. *Nature* 387, 296–299.
- Hickman, S.E., Allison, E.K., El Khoury, J., 2008. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *J. Neurosci.* 28, 8354–8360.
- Honda, R., Tanaka, H., Yasuda, H., 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. *FEBS Lett.* 420, 25–27.
- Huang, J.Y., Bruno, A.M., Patel, C.A., Huynh, A.M., Philibert, K.D., Glucksman, M.J., Marr, R.A., 2008. Human membrane metalloendopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40. *Neuroscience* 155, 258–262.
- Huang, J.Y., Hafez, D.M., James, B.D., Bennett, D.A., Marr, R.A., 2012. Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease. *J. Alzheimers Dis.* 28, 433–441.
- Ikeda, K., Emoto, N., Raharjo, S.B., Nurhantari, Y., Saiki, K., Yokoyama, M., Matsuo, M., 1999. Molecular identification and characterization of novel membrane-bound metalloprotease, the soluble secreted form of which hydrolyzes a variety of vasoactive peptides. *J. Biol. Chem.* 274, 32469–32477.
- Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P., Gerard, C., Hama, E., Lee, H.J., Saido, T.C., 2001. Metabolic regulation of brain Abeta by neprilysin. *Science* 292, 1550–1552.
- Janus, C., Pearson, J., McLaurin, J., Mathews, P.M., Jiang, Y., Schmidt, S.D., Chishti, M.A., Horne, P., Heslin, D., French, J., Mount, H.T., Nixon, R.A., Mercken, M., Bergeron, C., Fraser, P.E., St George-Hyslop, P., Westaway, D., 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. *Nature* 408, 979–982.
- Koba, C., Haruta, M., Matsunaga, Y., Matsumura, K., Haga, E., Sasaki, Y., Ikeda, T., Takamatsu, K., Nishimura, Y., Senju, S., 2013. Therapeutic effect of human iPSC-cell-derived myeloid cells expressing IFN-beta against peritoneally disseminated cancer in xenograft models. *PLoS One* 8, e67567.
- Kubbutat, M.H., Jones, S.N., Vousden, K.H., 1997. Regulation of p53 stability by Mdm2. *Nature* 387, 299–303.
- Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Rozovsky, I., Trommer, B., Viola, K.L., Wals, P., Zhang, C., Finch, C.E., Krafft, G.A., Klein, W.L., 1998. Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. *Proc. Natl. Acad. Sci. U. S. A.* 95, 6448–6453.
- Lebson, L., Nash, K., Kamath, S., Herber, D., Carty, N., Lee, D.C., Li, Q., Szekeres, K., Jinwal, U., Koren, J., Dickey, C.A., Gottschall, P.E., Morgan, D., Gordon, M.N., 2010. Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. *J. Neurosci.* 30, 9651–9658.
- Lee, J.K., Jin, H.K., Endo, S., Schuchman, E.H., Carter, J.E., Bae, J.S., 2010. Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer's disease mice by modulation of immune responses. *Stem Cells* 28, 329–343.
- Magga, J., Savchenko, E., Malm, T., Rolova, T., Pollari, E., Valonen, P., Lehtonen, S., Jantunen, E., Aarnio, J., Lehenkari, P., Koistinaho, M., Muona, A., Koistinaho, J., 2012. Production of monocytic cells from bone marrow stem cells: therapeutic usage in Alzheimer's disease. *J. Cell. Mol. Med.* 16, 1060–1073.
- Malm, T., Koistinaho, M., Muona, A., Magga, J., Koistinaho, J., 2010. The role and therapeutic potential of monocytic cells in Alzheimer's disease. *Glia* 58, 889–900.
- Mattiace, L.A., Davies, P., Dickson, D.W., 1990. Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. *Am. J. Pathol.* 136, 1101–1114.
- Miyoshi, H., Blomer, U., Takahashi, M., Gage, F.H., Verma, I.M., 1998. Development of a self-inactivating lentivirus vector. *J. Virol.* 72, 8150–8157.
- Mizuno, T., Kurotani, T., Komatsu, Y., Kawanokuchi, J., Kato, H., Mitsuma, N., Suzumura, A., 2004. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. *Neuropharmacology* 46, 404–411.
- Morgan, D., Diamond, D.M., Gottschall, P.E., Ugen, K.E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., Arendash, G.W.,

2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. *Nature* 408, 982–985.
- Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., Wang, L., Blesch, A., Kim, A., Conner, J.M., Rockenstein, E., Chao, M.V., Koo, E.H., Geschwind, D., Masliah, E., Chiba, A.A., Tuszynski, M.H., 2009. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. *Nat. Med.* 15, 331–337.
- Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O., 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. *Nat. Med.* 9, 448–452.
- Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* 26, 10129–10140.
- Perlmutter, L.S., Barron, E., Chui, H.C., 1990. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. *Neurosci. Lett.* 119, 32–36.
- Reddy, V.P., Zhu, X., Perry, G., Smith, M.A., 2009. Oxidative stress in diabetes and Alzheimer's disease. *J. Alzheimers Dis.* 16, 763–774.
- Robinson, S.R., Bishop, G.M., Lee, H.G., Munch, G., 2004. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. *Neurobiol. Aging* 25, 609–615.
- Salloway, S., Sperling, R., Gilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L.S., Doody, R., van Dyck, C.H., Mulnard, R., Barakos, J., Gregg, K.M., Liu, E., Lieberburg, I., Schenk, D., Black, R., Grundman, M., Bapineuzumab 201 Clinical Trial, I, 2009. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology* 73, 2061–2070.
- Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Liao, Z., Lieberburg, I., Motter, R., Mutter, L., Soriano, F., Shopp, G., Vasquez, N., Vandeventer, C., Walker, S., Wogulis, M., Yednock, T., Games, D., Seubert, P., 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. *Nature* 400, 173–177.
- Senju, S., Haruta, M., Matsunaga, Y., Fukushima, S., Ikeda, T., Takahashi, K., Okita, K., Yamanaka, S., Nishimura, Y., 2009. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. *Stem Cells* 27, 1021–1031.
- Senju, S., Haruta, M., Matsumura, K., Matsunaga, Y., Fukushima, S., Ikeda, T., Takamatsu, K., Irie, A., Nishimura, Y., 2011. Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy. *Gene Ther.* 18, 874–883.
- Simard, A.R., Rivest, S., 2004. Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia. *FASEB J.* 18, 998–1000.
- Stine Jr., W.B., Dahlgren, K.N., Krafft, G.A., LaDu, M.J., 2003. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. *J. Biol. Chem.* 278, 11612–11622.
- Takata, K., Kitamura, Y., Yanagisawa, D., Morikawa, S., Morita, M., Inubushi, T., Tsuchiya, D., Chishiro, S., Saeki, M., Taniguchi, T., Shimohama, S., Tooyama, I., 2007. Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. *FEBS Lett.* 581, 475–478.
- Takeda, S., Sato, N., Ikimura, K., Nishino, H., Rakugi, H., Morishita, R., 2011. Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse. *Neuroscience* 186, 110–119.
- Tanzi, R.E., Bertram, L., 2005. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell* 120, 545–555.
- Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416, 535–539.
- Yan, P., Hu, X., Song, H., Yin, K., Bateman, R.J., Cirrito, J.R., Xiao, Q., Hsu, F.F., Turk, J.W., Xu, J., Hsu, C.Y., Holtzman, D.M., Lee, J.M., 2006. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. *J. Biol. Chem.* 281, 24566–24574.
- Zahs, K.R., Ashe, K.H., 2013. beta-Amyloid oligomers in aging and Alzheimer's disease. *Front. Aging Neurosci.* 5, 28.
- Zotova, E., Holmes, C., Johnston, D., Neal, J.W., Nicoll, J.A., Boche, D., 2011. Microglial alterations in human Alzheimer's disease following Abeta42 immunization. *Neuropathol. Appl. Neurobiol.* 37, 513–524.



Tailor the adaptive immune response with
Vaccine Adjuvants



THE JOURNAL OF
IMMUNOLOGY

This information is current as
of September 3, 2014.

Therapy of Peritoneally Disseminated Colon Cancer by TAP-Deficient Embryonic Stem Cell-Derived Macrophages in Allogeneic Recipients

Eriko Haga, Yuko Endo, Miwa Haruta, Chihiro Koba, Keiko
Matsumura, Koutaro Takamatsu, Tokunori Ikeda, Yasuharu
Nishimura and Satoru Senju

J Immunol 2014; 193:2024-2033; Prepublished online 16
July 2014;
doi: 10.4049/jimmunol.1303473
<http://www.jimmunol.org/content/193/4/2024>

-
- Supplementary Material** <http://www.jimmunol.org/content/suppl/2014/07/16/content.1303473.DCSupplemental.html>
- References** This article **cites 53 articles**, 23 of which you can access for free at:
<http://www.jimmunol.org/content/193/4/2024.full#ref-list-1>
- Subscriptions** Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscriptions>
- Permissions** Submit copyright permission requests at:
<http://www.aai.org/ji/copyright.html>
- Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/cgi/alerts/etoc>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
9650 Rockville Pike, Bethesda, MD 20814-3994.
Copyright © 2014 by The American Association of
Immunologists, Inc. All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.

